SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals
Abstract Background Cancer cells are characterized by aberrant activation of lipid biosynthesis, producing saturated fatty acids and monounsaturated fatty acids via stearoyl-CoA desaturases (SCD) for regulating metabolic and signaling platforms. SCD1 overexpression functions as an oncogene in lung c...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-04-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12935-019-0809-y |
id |
doaj-19c626a8e73c44d89b6012742614ce3a |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kelin She Shenghua Fang Wei Du Xingxing Fan Jiaxi He Hui Pan Liyan Huang Ping He Jun Huang |
spellingShingle |
Kelin She Shenghua Fang Wei Du Xingxing Fan Jiaxi He Hui Pan Liyan Huang Ping He Jun Huang SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals Cancer Cell International SCD1 EGFR AKT EMT Lung cancer |
author_facet |
Kelin She Shenghua Fang Wei Du Xingxing Fan Jiaxi He Hui Pan Liyan Huang Ping He Jun Huang |
author_sort |
Kelin She |
title |
SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals |
title_short |
SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals |
title_full |
SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals |
title_fullStr |
SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals |
title_full_unstemmed |
SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals |
title_sort |
scd1 is required for egfr-targeting cancer therapy of lung cancer via re-activation of egfr/pi3k/akt signals |
publisher |
BMC |
series |
Cancer Cell International |
issn |
1475-2867 |
publishDate |
2019-04-01 |
description |
Abstract Background Cancer cells are characterized by aberrant activation of lipid biosynthesis, producing saturated fatty acids and monounsaturated fatty acids via stearoyl-CoA desaturases (SCD) for regulating metabolic and signaling platforms. SCD1 overexpression functions as an oncogene in lung cancer and predicts a poor clinical outcome. This study aimed to investigate the role of SCD1 inhibition by EGFR inhibitor (Gefitinib)-based anti-tumor therapy of lung cancer both in vitro and in vivo. Methods CCK-8 assay was performed to determine cell viability. The SCD1 mRNA level was detected by qPCR. The protein levels were assessed by Western blotting. E-cadherin and N-cadherin levels were determined by immunofluorescence. Apoptosis detection was conducted by flow cytometry. Cell migration or invasion was evaluated by transwell assay. The tumor sizes and tumor volumes were calculated in nude mice by subcutaneous injection of A549 cells transfected with vector of pcDNA3.1-SCD1 or negative control. Expression of Ki-67 was detected by immunohistochemistry. Result SCD1 up-regulated expression was observed in lung cancer cell lines. Cells with overexpressed SCD1 had high IC50 values for Gefitinib in A549 and H1573 cell lines. Overexpression of SCD1 inhibited Gefitinib-induced apoptosis, decreased cell vitality and impaired ability of migration and invasion, while these effects were counteracted by A939572. Mechanistically, SCD1 promoted the activation of proliferation and metastasis-related EGFR/PI3K/AKT signaling, and up-regulated epithelial to mesenchymal transition (EMT) phenotype in the two cell lines, which was restored by SCD1 inhibition. Furthermore, in spite of EGFR inhibition, overexpression of SCD1 in vivo significantly promoted tumor growth by activating EGFR/PI3K/AKT signaling in tumor tissues, but A939572 treatment restricted SCD1-induced tumor progression and inhibited EMT phenotype of cancer cells in vivo. Conclusion These findings indicated that inhibition of oncogene SCD1 is required for targeting EGFR therapy in lung cancer. |
topic |
SCD1 EGFR AKT EMT Lung cancer |
url |
http://link.springer.com/article/10.1186/s12935-019-0809-y |
work_keys_str_mv |
AT kelinshe scd1isrequiredforegfrtargetingcancertherapyoflungcancerviareactivationofegfrpi3kaktsignals AT shenghuafang scd1isrequiredforegfrtargetingcancertherapyoflungcancerviareactivationofegfrpi3kaktsignals AT weidu scd1isrequiredforegfrtargetingcancertherapyoflungcancerviareactivationofegfrpi3kaktsignals AT xingxingfan scd1isrequiredforegfrtargetingcancertherapyoflungcancerviareactivationofegfrpi3kaktsignals AT jiaxihe scd1isrequiredforegfrtargetingcancertherapyoflungcancerviareactivationofegfrpi3kaktsignals AT huipan scd1isrequiredforegfrtargetingcancertherapyoflungcancerviareactivationofegfrpi3kaktsignals AT liyanhuang scd1isrequiredforegfrtargetingcancertherapyoflungcancerviareactivationofegfrpi3kaktsignals AT pinghe scd1isrequiredforegfrtargetingcancertherapyoflungcancerviareactivationofegfrpi3kaktsignals AT junhuang scd1isrequiredforegfrtargetingcancertherapyoflungcancerviareactivationofegfrpi3kaktsignals |
_version_ |
1724950881061830656 |
spelling |
doaj-19c626a8e73c44d89b6012742614ce3a2020-11-25T02:02:52ZengBMCCancer Cell International1475-28672019-04-0119111110.1186/s12935-019-0809-ySCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signalsKelin She0Shenghua Fang1Wei Du2Xingxing Fan3Jiaxi He4Hui Pan5Liyan Huang6Ping He7Jun Huang8Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Research Institute of Respiratory Disease, China Key Laboratory of Respiratory Disease, National Center for Clinical Trials on Respiratory DiseasesAffiliated Cancer Hospital & Institute of Guangzhou Medical UniversityDepartment of Thoracic Surgery, Dongguan People’s HospitalState Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and TechnologyDepartment of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Research Institute of Respiratory Disease, China Key Laboratory of Respiratory Disease, National Center for Clinical Trials on Respiratory DiseasesDepartment of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Research Institute of Respiratory Disease, China Key Laboratory of Respiratory Disease, National Center for Clinical Trials on Respiratory DiseasesDepartment of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Research Institute of Respiratory Disease, China Key Laboratory of Respiratory Disease, National Center for Clinical Trials on Respiratory DiseasesDepartment of Pathology, The First Affiliated Hospital of Guangzhou Medical UniversityDepartment of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Research Institute of Respiratory Disease, China Key Laboratory of Respiratory Disease, National Center for Clinical Trials on Respiratory DiseasesAbstract Background Cancer cells are characterized by aberrant activation of lipid biosynthesis, producing saturated fatty acids and monounsaturated fatty acids via stearoyl-CoA desaturases (SCD) for regulating metabolic and signaling platforms. SCD1 overexpression functions as an oncogene in lung cancer and predicts a poor clinical outcome. This study aimed to investigate the role of SCD1 inhibition by EGFR inhibitor (Gefitinib)-based anti-tumor therapy of lung cancer both in vitro and in vivo. Methods CCK-8 assay was performed to determine cell viability. The SCD1 mRNA level was detected by qPCR. The protein levels were assessed by Western blotting. E-cadherin and N-cadherin levels were determined by immunofluorescence. Apoptosis detection was conducted by flow cytometry. Cell migration or invasion was evaluated by transwell assay. The tumor sizes and tumor volumes were calculated in nude mice by subcutaneous injection of A549 cells transfected with vector of pcDNA3.1-SCD1 or negative control. Expression of Ki-67 was detected by immunohistochemistry. Result SCD1 up-regulated expression was observed in lung cancer cell lines. Cells with overexpressed SCD1 had high IC50 values for Gefitinib in A549 and H1573 cell lines. Overexpression of SCD1 inhibited Gefitinib-induced apoptosis, decreased cell vitality and impaired ability of migration and invasion, while these effects were counteracted by A939572. Mechanistically, SCD1 promoted the activation of proliferation and metastasis-related EGFR/PI3K/AKT signaling, and up-regulated epithelial to mesenchymal transition (EMT) phenotype in the two cell lines, which was restored by SCD1 inhibition. Furthermore, in spite of EGFR inhibition, overexpression of SCD1 in vivo significantly promoted tumor growth by activating EGFR/PI3K/AKT signaling in tumor tissues, but A939572 treatment restricted SCD1-induced tumor progression and inhibited EMT phenotype of cancer cells in vivo. Conclusion These findings indicated that inhibition of oncogene SCD1 is required for targeting EGFR therapy in lung cancer.http://link.springer.com/article/10.1186/s12935-019-0809-ySCD1EGFRAKTEMTLung cancer |